Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026)
Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -14.68% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -49.97% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -49.30% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.97% |
| Mar 31, 2026 | -130.26% |
| Dec 31, 2025 | -5.91% |
| Sep 30, 2025 | 24.55% |
| Jun 30, 2025 | 9.02% |
| Mar 31, 2025 | 77.66% |
| Dec 31, 2024 | 52.52% |
| Sep 30, 2024 | 27.29% |
| Jun 30, 2024 | 35.83% |
| Mar 31, 2024 | -279.60% |
| Dec 31, 2023 | -128.00% |
| Sep 30, 2023 | 13.93% |
| Jun 30, 2023 | 7.34% |
| Mar 31, 2023 | 235.87% |
| Dec 31, 2022 | 10.72% |
| Sep 30, 2022 | -23.05% |
| Jun 30, 2022 | -51.93% |
| Mar 31, 2022 | 30.12% |
| Dec 31, 2021 | 35.97% |
| Sep 30, 2021 | -14.45% |